Ask about this productRelated genes to: IL31 protein (Mouse)
- Gene:
- IL31 NIH gene
- Name:
- interleukin 31
- Previous symbol:
- -
- Synonyms:
- IL-31
- Chromosome:
- 12q24.31
- Locus Type:
- gene with protein product
- Date approved:
- 2003-11-06
- Date modifiied:
- 2014-11-19
Related products to: IL31 protein (Mouse)
Related articles to: IL31 protein (Mouse)
- Systemic immunomodulatory treatments are widely used in canine atopic dermatitis (cAD), but treatment-associated differences in circulating cytokine profiles remain unclear. This cross-sectional study compared serum cytokine concentrations in 143 dogs: Healthy ( = 28), Untreated AD ( = 27), Prednisolone ( = 23), Oclacitinib ( = 29), Lokivetmab ( = 19), and Cyclosporine ( = 17). Serum concentrations of IFN-γ, IL-10, IL-13, IL-31, and TGF-β1 were quantified using enzyme-linked immunosorbent assays. pVAS and CADESI-04 were compared among the five cAD groups. All five cytokines differed significantly among the six groups. The Prednisolone group had lower pVAS scores than the Untreated AD group ( = 0.002) and the Cyclosporine group ( = 0.001), despite having the highest median serum IL-31 concentration (163.9 pg/mL), which was significantly higher than that in each of the other groups ( ≤ 0.003). The Prednisolone group showed lower IL-13 concentrations than the Healthy and Untreated AD groups (both = 0.001). IFN-γ concentrations were lower in the Oclacitinib, Lokivetmab, and Cyclosporine groups than in the Healthy group ( ≤ 0.002). Serum cytokine profiles differed among groups defined by treatment status; however, these cross-sectional differences cannot be interpreted as direct treatment effects. The discordance between pVAS and serum IL-31 in the Prednisolone group indicates that circulating cytokine concentrations may not consistently parallel concurrent clinical severity and should be interpreted as a hypothesis-generating observation rather than an established biological relationship. Longitudinal studies are needed to clarify whether these profiles reflect treatment exposure, underlying disease heterogeneity, or both. - Source: PubMed
Publication date: 2026/08/03
Ko Jae-YunKang Min-HeeLee Kwang-SupPark Hee-Myung - Cancer-associated pruritus (CAP) is defined as pruritus attributable to an underlying malignancy or presenting as a paraneoplastic process, usually without primary skin lesions. Persistent pruritus is a common and burdensome trait of numerous neoplasms. It is most commonly seen in hematologic cancers, including Hodgkin lymphoma, polycythemia vera, and cutaneous T-cell lymphoma, as well as some solid tumors, including cholangiocarcinoma and skin cancers. Mechanistically, this chronic pruritus is largely the result of type-2 pruritogenic cytokines, in particular IL-13, IL-31, and IL-4. In many cases, these are the master messengers of pruriceptive neurons. This leads to molding immune responses through effector cells including T helper type 2 lymphocytes, mast cells, and eosinophils. Herein, we review the contemporary advances in the understanding of CAP pathophysiology, its potential molecular and cellular targets, and evolving therapies. - Source: PubMed
Publication date: 2026/08/10
Ho Chih-YiPham Quoc Thao TrangWeng Hao-Jui - Neuroinflammation plays an important role in the pathobiology of Progressive Supranuclear Palsy Syndrome (PSP-S). However, it is not adequately known whether peripheral inflammation correlates to neuroinflammation in PSP-S. This study aimed to examine a link between peripheral and brain inflammation in PSP-S by integrating blood and cerebrospinal fluid (CSF) inflammatory profile and Positron Emission Tomography (PET)-Magnetic Resonance Imaging (MRI) (PET-MRI). - Source: PubMed
Publication date: 2026/07/23
Dey SaikatKumar AishwaryaKumar PardeepKavya Paranthaman VMondal SandipanHolla Vikram VKamble NitishMahale RohanPal Pramod KYadav RaviDebnath Monojit - - Source: PubMed
Publication date: 2026/08/05
Hagino TeppeiTakahashi YoheiSaeki HidehisaFujimoto EitaKanda Naoko - Atopic dermatitis (AD) is a chronic inflammatory skin disorder marked by intense pruritus and episodic flares. While nemolizumab, an interleukin-31 (IL-31) inhibitor, has demonstrated efficacy in reducing itch severity, its broader effects on skin inflammation are not fully understood. - Source: PubMed
Burke Olivia MBeer JacobElman Scott A